Tesla stock booms to new high as analyst ups price target to $515
Tesla stock’s end-of-year rampage rolled on, with shares hitting another new high based on optimism for Tesla's "autonomous opportunity" and a Trump-controlled executive branch.
Tesla stock’s end-of-year rampage rolled on, with shares hitting another new high based on optimism for Tesla's "autonomous opportunity" and a Trump-controlled executive branch.
CVS Health's Caremark, Cigna's Express Scripts and UnitedHealth Group's Optum control the majority of the U.S. pharmacy benefit market, with their parent companies also operating health insurance and pharmacy businesses. Pharmacy benefit managers negotiate drug costs with pharmacies and drug manufacturers and help build drug coverage lists for health plans, mostly on behalf of employers and the government.
The benchmark US stock measures were tracking in the green before Monday's opening bell as traders a
US private-sector output rose at the fastest pace since March 2022 in December despite a steepening
Ford Motor shares fell Monday after analysts at Jefferies downgraded the stock, pointing to inventory issues.
Last week's bond-market wobble hasn't damped bets on a year-end stocks rally, with more gains expected in 2025.
On Friday, Nasdaq Inc’s (NASDAQ:NDAQ) annual reconstitution of the Nasdaq-100 Index will become effective before the market opens on December 23. Illumina, Inc. (NASDAQ:ILMN) was removed from the index. Year to date, the stock has increased around 8%, underperforming iShares Core S&P Mid-Cap ETF (NYSE:IJH). The provider of DNA sequencing and array-based technologies has been in the news due to its controversial multi-billion dollar deal to acquire cancer test maker Grail Inc (NASDAQ:GRAL). Also
Broadcom shares surged to a fresh record high Monday as the chipmaker’s post-earnings rally continued.
On Friday, Nasdaq Inc's (NASDAQ:NDAQ) annual reconstitution of the Nasdaq-100 Index will become effective before the market opens on December 23. As a result, Moderna Inc. (NASDAQ:MRNA) was removed from the index. Year to date, Moderna stock has plunged over 60%, with a 52-week low-high of $35.8-$170.47, as per data from Benzinga Pro. Recently, Moderna and several other stocks witnessed a decline as Robert F. Kennedy Jr.'s, Donald Trump's nomination to lead the Department of Health and Human Ser
Prepare now for stocks to sell off at the start of 2025.